APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fidaxomicin

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Fidaxomicin Market Analysis and Forecast 2026-2032

27 December 2025199 pages

Choose your research edition.

Industry ResearchFidaxomicin Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Fidaxomicin Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Fidaxomicin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fidaxomicin Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Fidaxomicin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Fidaxomicin market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Fidaxomicin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Fidaxomicin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Fidaxomicin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Fidaxomicin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Fidaxomicin include Merck, Livzon Group, Tecoland, Rochem, Optimer Pharmaceuticals, Olon, BrightGene Bio-Medical Technology and Astellas, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Fidaxomicin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Fidaxomicin, also provides the sales of main regions and countries. Of the upcoming market potential for Fidaxomicin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Fidaxomicin sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Fidaxomicin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Fidaxomicin sales, projected growth trends, production technology, application and end-user industry.

Fidaxomicin Segment by Company

Merck

Livzon Group

Tecoland

Rochem

Optimer Pharmaceuticals

Olon

BrightGene Bio-Medical Technology

Astellas

Fidaxomicin Segment by Type

Purity:90%

Purity:95%

Others

Fidaxomicin Segment by Application

Hospital

Retail Pharmacies

Fidaxomicin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fidaxomicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fidaxomicin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fidaxomicin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Fidaxomicin in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Fidaxomicin manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Fidaxomicin sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Fidaxomicin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Purity:90% Major Manufacturers Table 3. Purity:95% Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Fidaxomicin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Manufacturers Table 7. Retail Pharmacies Major Manufacturers Table 8. Fidaxomicin Industry Trends Table 9. Fidaxomicin Industry Drivers Table 10. Fidaxomicin Industry Opportunities and Challenges Table 11. Fidaxomicin Industry Restraints Table 12. Global Fidaxomicin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Fidaxomicin Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Fidaxomicin Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Fidaxomicin Revenue Market Share by Region (2021-2026) Table 16. Global Fidaxomicin Revenue Market Share by Region (2027-2032) Table 17. Global Fidaxomicin Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Pcs) Table 18. Global Fidaxomicin Sales by Region (2021-2026) & (W Pcs) Table 19. Global Fidaxomicin Sales by Region (2027-2032) & (W Pcs) Table 20. Global Fidaxomicin Sales Market Share by Region (2021-2026) Table 21. Global Fidaxomicin Sales Market Share by Region (2027-2032) Table 22. Global Fidaxomicin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Fidaxomicin Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Fidaxomicin Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Fidaxomicin Sales Market Share by Manufacturers (2021-2026) Table 26. Global Fidaxomicin Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 27. Global Fidaxomicin Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Fidaxomicin Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Fidaxomicin Manufacturers, Product Type & Application Table 30. Global Fidaxomicin Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Fidaxomicin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Fidaxomicin Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Fidaxomicin Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Fidaxomicin Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Fidaxomicin Revenue Market Share by Type (2021-2026) Table 37. Global Fidaxomicin Revenue Market Share by Type (2027-2032) Table 38. Global Fidaxomicin Sales by Type 2021 VS 2025 VS 2032 (W Pcs) Table 39. Global Fidaxomicin Sales by Type (2021-2026) & (W Pcs) Table 40. Global Fidaxomicin Sales by Type (2027-2032) & (W Pcs) Table 41. Global Fidaxomicin Sales Market Share by Type (2021-2026) Table 42. Global Fidaxomicin Sales Market Share by Type (2027-2032) Table 43. Global Fidaxomicin Price by Type (2021-2026) & (US$/Pcs) Table 44. Global Fidaxomicin Price by Type (2027-2032) & (US$/Pcs) Table 45. Global Fidaxomicin Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Fidaxomicin Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Fidaxomicin Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Fidaxomicin Revenue Market Share by Application (2021-2026) Table 49. Global Fidaxomicin Revenue Market Share by Application (2027-2032) Table 50. Global Fidaxomicin Sales by Application 2021 VS 2025 VS 2032 (W Pcs) Table 51. Global Fidaxomicin Sales by Application (2021-2026) & (W Pcs) Table 52. Global Fidaxomicin Sales by Application (2027-2032) & (W Pcs) Table 53. Global Fidaxomicin Sales Market Share by Application (2021-2026) Table 54. Global Fidaxomicin Sales Market Share by Application (2027-2032) Table 55. Global Fidaxomicin Price by Application (2021-2026) & (US$/Pcs) Table 56. Global Fidaxomicin Price by Application (2027-2032) & (US$/Pcs) Table 57. Merck Company Information Table 58. Merck Business Overview Table 59. Merck Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 60. Merck Fidaxomicin Product Portfolio Table 61. Merck Recent Development Table 62. Livzon Group Company Information Table 63. Livzon Group Business Overview Table 64. Livzon Group Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 65. Livzon Group Fidaxomicin Product Portfolio Table 66. Livzon Group Recent Development Table 67. Tecoland Company Information Table 68. Tecoland Business Overview Table 69. Tecoland Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 70. Tecoland Fidaxomicin Product Portfolio Table 71. Tecoland Recent Development Table 72. Rochem Company Information Table 73. Rochem Business Overview Table 74. Rochem Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 75. Rochem Fidaxomicin Product Portfolio Table 76. Rochem Recent Development Table 77. Optimer Pharmaceuticals Company Information Table 78. Optimer Pharmaceuticals Business Overview Table 79. Optimer Pharmaceuticals Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 80. Optimer Pharmaceuticals Fidaxomicin Product Portfolio Table 81. Optimer Pharmaceuticals Recent Development Table 82. Olon Company Information Table 83. Olon Business Overview Table 84. Olon Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 85. Olon Fidaxomicin Product Portfolio Table 86. Olon Recent Development Table 87. BrightGene Bio-Medical Technology Company Information Table 88. BrightGene Bio-Medical Technology Business Overview Table 89. BrightGene Bio-Medical Technology Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 90. BrightGene Bio-Medical Technology Fidaxomicin Product Portfolio Table 91. BrightGene Bio-Medical Technology Recent Development Table 92. Astellas Company Information Table 93. Astellas Business Overview Table 94. Astellas Fidaxomicin Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 95. Astellas Fidaxomicin Product Portfolio Table 96. Astellas Recent Development Table 97. North America Fidaxomicin Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Fidaxomicin Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Fidaxomicin Sales by Type (2021-2026) & (W Pcs) Table 100. North America Fidaxomicin Sales by Type (2027-2032) & (W Pcs) Table 101. North America Fidaxomicin Sales Price by Type (2021-2026) & (US$/Pcs) Table 102. North America Fidaxomicin Sales Price by Type (2027-2032) & (US$/Pcs) Table 103. North America Fidaxomicin Revenue by Application (2021-2026) & (US$ Million) Table 104. North America Fidaxomicin Revenue by Application (2027-2032) & (US$ Million) Table 105. North America Fidaxomicin Sales by Application (2021-2026) & (W Pcs) Table 106. North America Fidaxomicin Sales by Application (2027-2032) & (W Pcs) Table 107. North America Fidaxomicin Sales Price by Application (2021-2026) & (US$/Pcs) Table 108. North America Fidaxomicin Sales Price by Application (2027-2032) & (US$/Pcs) Table 109. North America Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Fidaxomicin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 111. North America Fidaxomicin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 112. North America Fidaxomicin Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 113. North America Fidaxomicin Sales by Country (2021-2026) & (W Pcs) Table 114. North America Fidaxomicin Sales by Country (2027-2032) & (W Pcs) Table 115. North America Fidaxomicin Sales Price by Country (2021-2026) & (US$/Pcs) Table 116. North America Fidaxomicin Sales Price by Country (2027-2032) & (US$/Pcs) Table 117. United States Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 118. Canada Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 119. Mexico Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 120. Europe Fidaxomicin Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Fidaxomicin Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Fidaxomicin Sales by Type (2021-2026) & (W Pcs) Table 123. Europe Fidaxomicin Sales by Type (2027-2032) & (W Pcs) Table 124. Europe Fidaxomicin Sales Price by Type (2021-2026) & (US$/Pcs) Table 125. Europe Fidaxomicin Sales Price by Type (2027-2032) & (US$/Pcs) Table 126. Europe Fidaxomicin Revenue by Application (2021-2026) & (US$ Million) Table 127. Europe Fidaxomicin Revenue by Application (2027-2032) & (US$ Million) Table 128. Europe Fidaxomicin Sales by Application (2021-2026) & (W Pcs) Table 129. Europe Fidaxomicin Sales by Application (2027-2032) & (W Pcs) Table 130. Europe Fidaxomicin Sales Price by Application (2021-2026) & (US$/Pcs) Table 131. Europe Fidaxomicin Sales Price by Application (2027-2032) & (US$/Pcs) Table 132. Europe Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Europe Fidaxomicin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 134. Europe Fidaxomicin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 135. Europe Fidaxomicin Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 136. Europe Fidaxomicin Sales by Country (2021-2026) & (W Pcs) Table 137. Europe Fidaxomicin Sales by Country (2027-2032) & (W Pcs) Table 138. Europe Fidaxomicin Sales Price by Country (2021-2026) & (US$/Pcs) Table 139. Europe Fidaxomicin Sales Price by Country (2027-2032) & (US$/Pcs) Table 140. Germany Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 141. France Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 142. U.K. Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 143. Italy Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 144. Russia Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 145. Spain Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 146. Netherlands Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 147. Switzerland Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 148. Sweden Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 149. Poland Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 150. China Fidaxomicin Revenue by Type (2021-2026) & (US$ Million) Table 151. China Fidaxomicin Revenue by Type (2027-2032) & (US$ Million) Table 152. China Fidaxomicin Sales by Type (2021-2026) & (W Pcs) Table 153. China Fidaxomicin Sales by Type (2027-2032) & (W Pcs) Table 154. China Fidaxomicin Sales Price by Type (2021-2026) & (US$/Pcs) Table 155. China Fidaxomicin Sales Price by Type (2027-2032) & (US$/Pcs) Table 156. China Fidaxomicin Revenue by Application (2021-2026) & (US$ Million) Table 157. China Fidaxomicin Revenue by Application (2027-2032) & (US$ Million) Table 158. China Fidaxomicin Sales by Application (2021-2026) & (W Pcs) Table 159. China Fidaxomicin Sales by Application (2027-2032) & (W Pcs) Table 160. China Fidaxomicin Sales Price by Application (2021-2026) & (US$/Pcs) Table 161. China Fidaxomicin Sales Price by Application (2027-2032) & (US$/Pcs) Table 162. Asia Fidaxomicin Revenue by Type (2021-2026) & (US$ Million) Table 163. Asia Fidaxomicin Revenue by Type (2027-2032) & (US$ Million) Table 164. Asia Fidaxomicin Sales by Type (2021-2026) & (W Pcs) Table 165. Asia Fidaxomicin Sales by Type (2027-2032) & (W Pcs) Table 166. Asia Fidaxomicin Sales Price by Type (2021-2026) & (US$/Pcs) Table 167. Asia Fidaxomicin Sales Price by Type (2027-2032) & (US$/Pcs) Table 168. Asia Fidaxomicin Revenue by Application (2021-2026) & (US$ Million) Table 169. Asia Fidaxomicin Revenue by Application (2027-2032) & (US$ Million) Table 170. Asia Fidaxomicin Sales by Application (2021-2026) & (W Pcs) Table 171. Asia Fidaxomicin Sales by Application (2027-2032) & (W Pcs) Table 172. Asia Fidaxomicin Sales Price by Application (2021-2026) & (US$/Pcs) Table 173. Asia Fidaxomicin Sales Price by Application (2027-2032) & (US$/Pcs) Table 174. Asia Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. Asia Fidaxomicin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. Asia Fidaxomicin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. Asia Fidaxomicin Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 178. Asia Fidaxomicin Sales by Country (2021-2026) & (W Pcs) Table 179. Asia Fidaxomicin Sales by Country (2027-2032) & (W Pcs) Table 180. Asia Fidaxomicin Sales Price by Country (2021-2026) & (US$/Pcs) Table 181. Asia Fidaxomicin Sales Price by Country (2027-2032) & (US$/Pcs) Table 182. Japan Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 183. South Korea Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 184. India Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 185. Australia Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 186. Taiwan Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 187. Southeast Asia Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 188. SAMEA Fidaxomicin Revenue by Type (2021-2026) & (US$ Million) Table 189. SAMEA Fidaxomicin Revenue by Type (2027-2032) & (US$ Million) Table 190. SAMEA Fidaxomicin Sales by Type (2021-2026) & (W Pcs) Table 191. SAMEA Fidaxomicin Sales by Type (2027-2032) & (W Pcs) Table 192. SAMEA Fidaxomicin Sales Price by Type (2021-2026) & (US$/Pcs) Table 193. SAMEA Fidaxomicin Sales Price by Type (2027-2032) & (US$/Pcs) Table 194. SAMEA Fidaxomicin Revenue by Application (2021-2026) & (US$ Million) Table 195. SAMEA Fidaxomicin Revenue by Application (2027-2032) & (US$ Million) Table 196. SAMEA Fidaxomicin Sales by Application (2021-2026) & (W Pcs) Table 197. SAMEA Fidaxomicin Sales by Application (2027-2032) & (W Pcs) Table 198. SAMEA Fidaxomicin Sales Price by Application (2021-2026) & (US$/Pcs) Table 199. SAMEA Fidaxomicin Sales Price by Application (2027-2032) & (US$/Pcs) Table 200. SAMEA Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 201. SAMEA Fidaxomicin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 202. SAMEA Fidaxomicin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 203. SAMEA Fidaxomicin Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 204. SAMEA Fidaxomicin Sales by Country (2021-2026) & (W Pcs) Table 205. SAMEA Fidaxomicin Sales by Country (2027-2032) & (W Pcs) Table 206. SAMEA Fidaxomicin Sales Price by Country (2021-2026) & (US$/Pcs) Table 207. SAMEA Fidaxomicin Sales Price by Country (2027-2032) & (US$/Pcs) Table 208. Brazil Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 209. Argentina Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 210. Chile Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 211. Colombia Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 212. Peru Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 213. Saudi Arabia Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 214. Israel Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 215. UAE Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 216. Turkey Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 217. Iran Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 218. Egypt Fidaxomicin Revenue (2021-2032) & (US$ Million) Table 219. Key Raw Materials Table 220. Raw Materials Key Suppliers Table 221. Fidaxomicin Distributors List Table 222. Fidaxomicin Customers List Table 223. Research Programs/Design for This Report Table 224. Authors List of This Report Table 225. Secondary Sources Table 226. Primary Sources List of Figures Figure 1. Fidaxomicin Image Figure 2. Global Fidaxomicin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fidaxomicin Market Size Share 2021 VS 2025 VS 2032 Figure 4. Purity:90% Image Figure 5. Purity:95% Image Figure 6. Others Image Figure 7. Global Fidaxomicin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Fidaxomicin Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Retail Pharmacies Image Figure 11. Global Fidaxomicin Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Fidaxomicin Revenue (2021-2032) & (US$ Million) Figure 13. Global Fidaxomicin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Fidaxomicin Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Fidaxomicin Revenue Market Share by Region (2021-2032) Figure 16. Global Fidaxomicin Sales (2021-2032) & (W Pcs) Figure 17. Global Fidaxomicin Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Figure 18. Global Fidaxomicin Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Fidaxomicin Sales YoY (2021-2032) & (W Pcs) Figure 20. Europe Fidaxomicin Sales YoY (2021-2032) & (W Pcs) Figure 21. China Fidaxomicin Sales YoY (2021-2032) & (W Pcs) Figure 22. Asia (Excluding China) Fidaxomicin Sales YoY (2021-2032) & (W Pcs) Figure 23. South America, Middle East and Africa Fidaxomicin Sales YoY (2021-2032) & (W Pcs) Figure 24. Global Fidaxomicin Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Fidaxomicin Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Fidaxomicin Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Fidaxomicin Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Fidaxomicin Revenue Market Share by Type (2021-2032) Figure 30. Global Fidaxomicin Sales by Type (2021 VS 2025 VS 2032) & (W Pcs) Figure 31. Global Fidaxomicin Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Fidaxomicin Sales Market Share by Type (2021-2032) Figure 33. Global Fidaxomicin Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Fidaxomicin Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Fidaxomicin Revenue Market Share by Application (2021-2032) Figure 36. Global Fidaxomicin Sales by Application (2021 VS 2025 VS 2032) & (W Pcs) Figure 37. Global Fidaxomicin Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Fidaxomicin Sales Market Share by Application (2021-2032) Figure 39. North America Fidaxomicin Revenue Share by Type (2021-2032) Figure 40. North America Fidaxomicin Sales Share by Type (2021-2032) Figure 41. North America Fidaxomicin Revenue Share by Application (2021-2032) Figure 42. North America Fidaxomicin Sales Share by Application (2021-2032) Figure 43. North America Fidaxomicin Revenue Share by Country (2021-2032) Figure 44. North America Fidaxomicin Sales Share by Country (2021-2032) Figure 45. Europe Fidaxomicin Revenue Share by Type (2021-2032) Figure 46. Europe Fidaxomicin Sales Share by Type (2021-2032) Figure 47. Europe Fidaxomicin Revenue Share by Application (2021-2032) Figure 48. Europe Fidaxomicin Sales Share by Application (2021-2032) Figure 49. Europe Fidaxomicin Revenue Share by Country (2021-2032) Figure 50. Europe Fidaxomicin Sales Share by Country (2021-2032) Figure 51. China Fidaxomicin Revenue Share by Type (2021-2032) Figure 52. China Fidaxomicin Sales Share by Type (2021-2032) Figure 53. China Fidaxomicin Revenue Share by Application (2021-2032) Figure 54. China Fidaxomicin Sales Share by Application (2021-2032) Figure 55. Asia Fidaxomicin Revenue Share by Type (2021-2032) Figure 56. Asia Fidaxomicin Sales Share by Type (2021-2032) Figure 57. Asia Fidaxomicin Revenue Share by Application (2021-2032) Figure 58. Asia Fidaxomicin Sales Share by Application (2021-2032) Figure 59. Asia Fidaxomicin Revenue Share by Country (2021-2032) Figure 60. Asia Fidaxomicin Sales Share by Country (2021-2032) Figure 61. SAMEA Fidaxomicin Revenue Share by Type (2021-2032) Figure 62. SAMEA Fidaxomicin Sales Share by Type (2021-2032) Figure 63. SAMEA Fidaxomicin Revenue Share by Application (2021-2032) Figure 64. SAMEA Fidaxomicin Sales Share by Application (2021-2032) Figure 65. SAMEA Fidaxomicin Revenue Share by Country (2021-2032) Figure 66. SAMEA Fidaxomicin Sales Share by Country (2021-2032) Figure 67. Fidaxomicin Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Fidaxomicin Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Purity:90%
  • Purity:95%
  • Others
Applications
  • Hospital
  • Retail Pharmacies
Companies covered
  • Merck
  • Livzon Group
  • Tecoland
  • Rochem
  • Optimer Pharmaceuticals
  • Olon
  • BrightGene Bio-Medical Technology
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Fidaxomicin Market by Type
  3. 1.2.1 Global Fidaxomicin Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Purity:90%
  5. 1.2.3 Purity:95%
  6. 1.2.4 Others
  7. 1.3 Fidaxomicin Market by Application
  8. 1.3.1 Global Fidaxomicin Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Retail Pharmacies
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Fidaxomicin Market Dynamics
  1. 2.1 Fidaxomicin Industry Trends
  2. 2.2 Fidaxomicin Industry Drivers
  3. 2.3 Fidaxomicin Industry Opportunities and Challenges
  4. 2.4 Fidaxomicin Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Fidaxomicin Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Fidaxomicin Revenue by Region
  3. 3.2.1 Global Fidaxomicin Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Fidaxomicin Revenue by Region (2021-2026)
  5. 3.2.3 Global Fidaxomicin Revenue by Region (2027-2032)
  6. 3.2.4 Global Fidaxomicin Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Fidaxomicin Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Fidaxomicin Sales by Region
  9. 3.4.1 Global Fidaxomicin Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Fidaxomicin Sales by Region (2021-2026)
  11. 3.4.3 Global Fidaxomicin Sales by Region (2027-2032)
  12. 3.4.4 Global Fidaxomicin Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Fidaxomicin Revenue by Manufacturers
  2. 4.1.1 Global Fidaxomicin Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Fidaxomicin Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Fidaxomicin Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Fidaxomicin Sales by Manufacturers
  6. 4.2.1 Global Fidaxomicin Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Fidaxomicin Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Fidaxomicin Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Fidaxomicin Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Fidaxomicin Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Fidaxomicin Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Fidaxomicin Manufacturers, Product Type & Application
  13. 4.7 Global Fidaxomicin Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Fidaxomicin Market CR5 and HHI
  16. 4.8.2 2025 Fidaxomicin Tier 1, Tier 2, and Tier 3
5 Fidaxomicin Market by Type
  1. 5.1 Global Fidaxomicin Revenue by Type
  2. 5.1.1 Global Fidaxomicin Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Fidaxomicin Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Fidaxomicin Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Fidaxomicin Sales by Type
  6. 5.2.1 Global Fidaxomicin Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Fidaxomicin Sales by Type (2021-2032) & (W Pcs)
  8. 5.2.3 Global Fidaxomicin Sales Market Share by Type (2021-2032)
  9. 5.3 Global Fidaxomicin Price by Type
6 Fidaxomicin Market by Application
  1. 6.1 Global Fidaxomicin Revenue by Application
  2. 6.1.1 Global Fidaxomicin Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Fidaxomicin Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Fidaxomicin Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Fidaxomicin Sales by Application
  6. 6.2.1 Global Fidaxomicin Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Fidaxomicin Sales by Application (2021-2032) & (W Pcs)
  8. 6.2.3 Global Fidaxomicin Sales Market Share by Application (2021-2032)
  9. 6.3 Global Fidaxomicin Price by Application
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Merck Fidaxomicin Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Livzon Group
  8. 7.2.1 Livzon Group Company Information
  9. 7.2.2 Livzon Group Business Overview
  10. 7.2.3 Livzon Group Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Livzon Group Fidaxomicin Product Portfolio
  12. 7.2.5 Livzon Group Recent Developments
  13. 7.3 Tecoland
  14. 7.3.1 Tecoland Company Information
  15. 7.3.2 Tecoland Business Overview
  16. 7.3.3 Tecoland Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Tecoland Fidaxomicin Product Portfolio
  18. 7.3.5 Tecoland Recent Developments
  19. 7.4 Rochem
  20. 7.4.1 Rochem Company Information
  21. 7.4.2 Rochem Business Overview
  22. 7.4.3 Rochem Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Rochem Fidaxomicin Product Portfolio
  24. 7.4.5 Rochem Recent Developments
  25. 7.5 Optimer Pharmaceuticals
  26. 7.5.1 Optimer Pharmaceuticals Company Information
  27. 7.5.2 Optimer Pharmaceuticals Business Overview
  28. 7.5.3 Optimer Pharmaceuticals Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Optimer Pharmaceuticals Fidaxomicin Product Portfolio
  30. 7.5.5 Optimer Pharmaceuticals Recent Developments
  31. 7.6 Olon
  32. 7.6.1 Olon Company Information
  33. 7.6.2 Olon Business Overview
  34. 7.6.3 Olon Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Olon Fidaxomicin Product Portfolio
  36. 7.6.5 Olon Recent Developments
  37. 7.7 BrightGene Bio-Medical Technology
  38. 7.7.1 BrightGene Bio-Medical Technology Company Information
  39. 7.7.2 BrightGene Bio-Medical Technology Business Overview
  40. 7.7.3 BrightGene Bio-Medical Technology Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 BrightGene Bio-Medical Technology Fidaxomicin Product Portfolio
  42. 7.7.5 BrightGene Bio-Medical Technology Recent Developments
  43. 7.8 Astellas
  44. 7.8.1 Astellas Company Information
  45. 7.8.2 Astellas Business Overview
  46. 7.8.3 Astellas Fidaxomicin Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Astellas Fidaxomicin Product Portfolio
  48. 7.8.5 Astellas Recent Developments
8 North America
  1. 8.1 North America Fidaxomicin Market Size by Type
  2. 8.1.1 North America Fidaxomicin Revenue by Type (2021-2032)
  3. 8.1.2 North America Fidaxomicin Sales by Type (2021-2032)
  4. 8.1.3 North America Fidaxomicin Price by Type (2021-2032)
  5. 8.2 North America Fidaxomicin Market Size by Application
  6. 8.2.1 North America Fidaxomicin Revenue by Application (2021-2032)
  7. 8.2.2 North America Fidaxomicin Sales by Application (2021-2032)
  8. 8.2.3 North America Fidaxomicin Price by Application (2021-2032)
  9. 8.3 North America Fidaxomicin Market Size by Country
  10. 8.3.1 North America Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Fidaxomicin Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Fidaxomicin Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Fidaxomicin Market Size by Type
  2. 9.1.1 Europe Fidaxomicin Revenue by Type (2021-2032)
  3. 9.1.2 Europe Fidaxomicin Sales by Type (2021-2032)
  4. 9.1.3 Europe Fidaxomicin Price by Type (2021-2032)
  5. 9.2 Europe Fidaxomicin Market Size by Application
  6. 9.2.1 Europe Fidaxomicin Revenue by Application (2021-2032)
  7. 9.2.2 Europe Fidaxomicin Sales by Application (2021-2032)
  8. 9.2.3 Europe Fidaxomicin Price by Application (2021-2032)
  9. 9.3 Europe Fidaxomicin Market Size by Country
  10. 9.3.1 Europe Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Fidaxomicin Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Fidaxomicin Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Fidaxomicin Market Size by Type
  2. 10.1.1 China Fidaxomicin Revenue by Type (2021-2032)
  3. 10.1.2 China Fidaxomicin Sales by Type (2021-2032)
  4. 10.1.3 China Fidaxomicin Price by Type (2021-2032)
  5. 10.2 China Fidaxomicin Market Size by Application
  6. 10.2.1 China Fidaxomicin Revenue by Application (2021-2032)
  7. 10.2.2 China Fidaxomicin Sales by Application (2021-2032)
  8. 10.2.3 China Fidaxomicin Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Fidaxomicin Market Size by Type
  2. 11.1.1 Asia Fidaxomicin Revenue by Type (2021-2032)
  3. 11.1.2 Asia Fidaxomicin Sales by Type (2021-2032)
  4. 11.1.3 Asia Fidaxomicin Price by Type (2021-2032)
  5. 11.2 Asia Fidaxomicin Market Size by Application
  6. 11.2.1 Asia Fidaxomicin Revenue by Application (2021-2032)
  7. 11.2.2 Asia Fidaxomicin Sales by Application (2021-2032)
  8. 11.2.3 Asia Fidaxomicin Price by Application (2021-2032)
  9. 11.3 Asia Fidaxomicin Market Size by Country
  10. 11.3.1 Asia Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Fidaxomicin Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Fidaxomicin Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Fidaxomicin Market Size by Type
  2. 12.1.1 SAMEA Fidaxomicin Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Fidaxomicin Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Fidaxomicin Price by Type (2021-2032)
  5. 12.2 SAMEA Fidaxomicin Market Size by Application
  6. 12.2.1 SAMEA Fidaxomicin Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Fidaxomicin Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Fidaxomicin Price by Application (2021-2032)
  9. 12.3 SAMEA Fidaxomicin Market Size by Country
  10. 12.3.1 SAMEA Fidaxomicin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Fidaxomicin Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Fidaxomicin Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Fidaxomicin Value Chain Analysis
  2. 13.1.1 Fidaxomicin Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Fidaxomicin Production Mode & Process
  6. 13.2 Fidaxomicin Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Fidaxomicin Distributors
  9. 13.2.3 Fidaxomicin Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst